Business Context and Reporting Period
Company: Lucid Diagnostics Inc. (trading as PAVmed Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: November 8, 2024
Reporting Period: Event-based filing regarding a material definitive agreement and financing transaction.
Key Financial Metrics and Transaction Details
This filing details a refinancing transaction rather than standard periodic financial results. Key metrics include:
- Debt Instrument: Issuance of Senior Secured Convertible Notes ("2024 Convertible Notes").
- Interest Rate: 12.0% annual stated interest rate.
- Maturity: Five years from the date of issuance.
- Conversion Price: $1.00 per share of common stock (subject to adjustments).
- Principal Repayment: Bullet payment due at maturity; no amortization.
- Interest Payment: Quarterly in cash or, at holder's election, in common stock.
- Liquidity Covenant: Company must maintain available cash of at least $5.0 million while at least 25% of the principal is outstanding.
- Security: Notes are secured by a lien on all present and future tangible and intangible assets.
Material Changes and Transaction Purpose
The primary material change is the restructuring of the company's debt obligations:
- Redemption of Prior Debt: Lucid Diagnostics exercised its right to redeem its Senior Convertible Note issued in March 2023 ("2023 Convertible Note").
- Financing Source: The redemption is being funded by the proceeds from the new 2024 Convertible Notes issued to accredited investors.
- Commitment Status: As of the filing date, aggregate commitments from new investors exceed the redemption price required for the 2023 Note.
- Timeline: The company expects to complete the issuance and redemption within the "Optional Redemption Notice Period" (10 to 20 business days from November 8, 2024).
Guidance, Risks, and Unusual Items
Management Commentary and Conditions:
- Acceleration Risk: The 2024 Notes are subject to acceleration if the company fails to obtain a positive Medicare coverage decision for its EsoGuard product by the 18-month anniversary of issuance.
- Redemption Restrictions: The company cannot voluntarily repurchase or prepay the 2024 Notes until the last 6 months prior to maturity, except under specific fundamental transaction or stock price conditions (VWAP $\ge$ $10.00 for 20 of 30 days).
- Corporate Governance: Certain investors have the right to designate one individual to the Board of Directors.
- Lock-up: PAVmed has agreed not to sell common stock for six months following the offering.
- Registration Rights: The company must file a Form S-3 resale registration statement within 120 days of closing.
Forward-Looking Statements: The filing contains forward-looking statements regarding the completion of the transaction and future financial performance, which are subject to risks and uncertainties.
Investor Verification Checklist
- Verify the final closing date of the 2024 Convertible Notes and the successful redemption of the 2023 Convertible Note.
- Confirm the total principal amount of the 2024 Convertible Notes issued to determine the exact debt load.
- Monitor the company's progress toward a positive Medicare coverage decision for the EsoGuard product to assess the risk of debt acceleration.
- Review the company's cash position to ensure compliance with the $5.0 million liquidity covenant.
- Check for the filing of the Form S-3 registration statement within the required 120-day window.